Rheumatology Department (Pitié) (E²MOIS)
Clinical Epidemiology of Osteoarticular and Systemic Diseases
The team is invested in the clinical epidemiology of IJS diseases through two principal axes:
The evaluation of the human and societal impact of these diseases: this axe was motivated by the observation that these diseases were rather poorly assessed in many countries, notably France, compared to neoplastic, cardiovascular, neurodegenerative or infectious diseases. This led us to participate or settle different projects to better characterize their impact from a global and societal point-of-view, including economic aspects, as well as from an individual perspective, for which patient involvement is absolutely crucial.
The optimization of therapeutic management strategies, since the number of efficient therapies substantially increased during the last decade. This motivated the development of several multicenter therapeutic strategy trials in order to define the optimal treatment sequences for several joint or systemic diseases.
As defined, our research activities are mainly applied research, aiming:
- to increase the knowledge about IJS disorders, their consequences on both patients and Society,
- to better define management strategies, which is dramatically needed due to the price of the most efficient therapies.
With regards to this, our research targets health decision makers as well as physicians who care such patients.
Fields of interest
Human and societal impact of IJSDs, biodrug monitoring, economic evaluation, therapeutic strategy RCTs, pharmacoepidemiology of biodrugs, IJSD imaging, step-down strategies, patient-reported outcome
Contact infoAddress: Rheumatology Department, GRC-UPMC 08, Pavillon Benjamin Delessert, Hôpital Pitié-Salpêtrière, 83 boulevard de l’Hôpital
City: Paris cedex 13
Postal code: 75651
Telephone: +33 1 42 17 78 01
Fax: +33 1 42 17 78 02
- Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, Sibilia J, Bourgeois P, Fautrel B; CRI (Club Rhumatismes et Inflammation)
Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy
Arthritis Care Res (Hoboken) 65(5), 822-826 (2013)
- Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
Arthritis Res Ther. 14(6), R249 (2012)
- Fautrel B, Combe B, Rincheval N, Dougados M, ESPOIR Scientific Committee
Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data
Ann Rheum Dis. 2012 Mar;71(3):386-9.
- Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S, Bourgeois P, Fautrel B
Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity
Arthritis Rheum. 2012 Jan;64(1):67-76.
- Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P et al.
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
Ann Rheum Dis. 2012 Jan;71(1):4-12.
- Gandjbakhch F, Foltz V, Mallet A, Bourgeois P, Fautrel B
Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low disease activity with low-field MRI
Ann Rheum Dis. 2011 Dec;70(12):2159-62.